- Home
- CATX vs VYGR Comparison
CATX vs VYGR Comparison
Compare CATX & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATX | VYGR |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.1M | 226.8M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | CATX | VYGR |
|---|---|---|
| Price | $2.70 | $4.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $11.56 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 1.2M | 558.4K |
| Earning Date | 11-10-2025 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,075,000.00 | ★ $31,316,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $71.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $2.65 |
| 52 Week High | $5.39 | $5.96 |
Technical Indicators
Market Signals| Indicator | CATX | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 52.13 |
| Support Level | $2.25 | $3.56 |
| Resistance Level | $2.66 | $3.96 |
| Average True Range (ATR) | 0.22 | 0.26 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 60.56 | 77.21 |
Price Performance
Historical ComparisonAbout CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.